Brief: Ocumension Therapeutics Says Ot-202 Approved For Clinical Trial On Treatment Of Dry Eye In China
12/10/2021 07:27
Oct 12 (Reuters) - Ocumension Therapeutics 1477.HK :
* OT-202 APPROVED BY CENTER FOR DRUG EVALUATION OF NMPA TO
CONDUCT
CLINICAL TRIAL ON TREATMENT OF DRY EYE IN CHINA
Source text for Eikon: ID:nHKS7RqQH
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application